7-[(3-phenylpyrrolidin-1-yl)carbonyl]-1,6-naphthyridin-8-ol | 442911-07-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: 7-[(3-phenylpyrrolidin-1-yl)carbonyl]-1,6-naphthyridin-8-ol
• 英文别名: (8-Hydroxy-1,6-naphthyridin-7-yl)-(3-phenylpyrrolidin-1-yl)methanone
• CAS: 442911-07-1
• 化学式: C₁₉H₁₇N₃O₂
• 分子量: 319.363
• InChiKey: DQNLOQGKIXBPLZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  24
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  66.3
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• Aza-and polyaza-naphthalenyl carboxamides useful as HIV integrase inhibitors
  申请人：——

  公开号：US20040044207A1

  公开（公告）日：2004-03-04

  Aza- and polyaza-naphthalenyl carboxamide derivatives including certain quinoline carboxamide and naphthyridine carboxamide derivatives are described as inhibitors of HIV integrase and inhibitors of HIV replication. These compounds are useful in the prevention or treatment of infection by HIV and the treatment of AIDS, as compounds or pharmaceutically acceptable salts, or as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of preventing, treating, or delaying the onset of AIDS and methods of preventing or treating infection by HIV are also described.

  本文描述了包括某些喹啉羧酰胺和萘啶羧酰胺衍生物在内的Aza-和polyaza-萘基羧酰胺衍生物，作为HIV整合酶的抑制剂和HIV复制的抑制剂。这些化合物可作为化合物或药物可接受的盐，或作为药物组成部分，可选与其他抗病毒药物、免疫调节剂、抗生素或疫苗组合使用，用于预防或治疗HIV感染和治疗艾滋病。还描述了预防、治疗或延迟艾滋病发作的方法以及预防或治疗HIV感染的方法。
• 4-OXOQUINOLINE COMPOUND AND USE THEREOF AS PHARMACEUTICAL AGENT
  申请人：Japan Tobacco Inc.

  公开号：US20150174117A1

  公开（公告）日：2015-06-25

  An anti-HIV agent containing, as an active ingredient, a 4-oxoquinoline compound represented by the following formula [I] wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof. The compound of the present invention has HIV integrase inhibitory action and is useful as an anti-HIV agent for the prophylaxis or therapy of AIDS. Moreover, by a combined use with other anti-HIV agents such as protease inhibitors, reverse transcriptase inhibitors and the like, the compound can become a more effective anti-HIV agent. Since the compound has high inhibitory activity specific for integrases, it can provide a safe pharmaceutical agent with a fewer side effects for human.

  一种抗HIV剂，其活性成分为以下式[I]所代表的4-氧喹啉化合物，其中每个符号在规范中定义，或其药学上可接受的盐。本发明的化合物具有HIV整合酶抑制作用，并且可用作预防或治疗艾滋病的抗HIV剂。此外，通过与其他抗HIV剂（如蛋白酶抑制剂，逆转录酶抑制剂等）的联合使用，该化合物可以成为更有效的抗HIV剂。由于该化合物具有高度特异性的整合酶抑制活性，因此可以提供一种对人体副作用较少的安全药物。
• 4-OXOQUINOLINE COMPOUND AND USE THEREOF AS HIV INTEGRASE INHIBITOR
  申请人：SATOH Motohide

  公开号：US20130172344A1

  公开（公告）日：2013-07-04

  An anti-HIV agent containing, as an active ingredient, a 4-oxoquinoline compound represented by the following formula [I] wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof. The compound of the present invention has HIV integrase inhibitory action and is useful as an anti-HIV agent for the prophylaxis or therapy of AIDS. Moreover, by a combined use with other anti-HIV agents such as protease inhibitors, reverse transcriptase inhibitors and the like, the compound can become a more effective anti-HIV agent. Since the compound has high inhibitory activity specific for integrases, it can provide a safe pharmaceutical agent with a fewer side effects for human.

  一种抗HIV药剂，其含有以下式[I]所表示的4-氧喹啉化合物作为活性成分，其中每个符号如规范中所定义，或其药学上可接受的盐。本发明的化合物具有HIV整合酶抑制作用，可用于预防或治疗艾滋病的抗HIV药剂。此外，与其他抗HIV药剂（如蛋白酶抑制剂、反转录酶抑制剂等）联合使用，该化合物可以成为更有效的抗HIV药剂。由于该化合物具有针对整合酶的高抑制活性，因此可以提供一种对人体副作用更少的安全药物。
• Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
  申请人：Miyazaki Susumu

  公开号：US20080161311A1

  公开（公告）日：2008-07-03

  The present invention relates to a nitrogen-containing fused ring compound represented by the following formula [I] wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof, and an anti-HIV agent containing such compound. The compound of the present invention has an HIV integrase inhibitory activity, and is useful as an agent for the prophylaxis or treatment of AIDS, or as an anti-HIV agent. In addition, by the combined use with other anti-HIV agents such as a protease inhibitor, a reverse transcriptase inhibitor and the like, it can be a more effective anti-HIV agent. Because it shows integrase-specific high inhibitory activity, the compound can be a pharmaceutical agent safe on human body, which causes only a fewer side effects.

  本发明涉及一种含氮融合环化合物，其化学式如下[I]，其中每个符号如规范中定义，或其药学上可接受的盐，以及含有该化合物的抗HIV剂。本发明的化合物具有HIV整合酶抑制活性，可用作艾滋病的预防或治疗剂，或作为抗HIV剂。此外，与其他抗HIV剂如蛋白酶抑制剂、反转录酶抑制剂等联合使用，可成为更有效的抗HIV剂。由于它表现出整合酶特异性高的抑制活性，该化合物可成为一种对人体安全的药物，仅引起较少的副作用。
• Combination Therapy
  申请人：JAPAN TOBACCO INC.

  公开号：US20140364389A1

  公开（公告）日：2014-12-11

  The present invention relates to a combination therapy for treating an HIV infection or inhibiting integrase comprising (S)-6-(3-Chloro-2-fluorobenzyl)-1-(1-hydroxymethyl-2-methylpropyl)-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (“Compound A”) or a pharmaceutically acceptable solvate or salt thereof in combination with at least one other anti-HIV agent. In some embodiments of the present invention, the other anti-HIV agents are chosen from reverse transcriptase inhibitors and protease inhibitors. In certain embodiments of the present invention, the other anti-HIV agents are chosen from AZT, 3TC, PMPA, efavirenz, indinavir, nelfinavir, a combination of AZT/3TC, and a combination of PMPA/3TC. Since Compound A has a high inhibitory activity specific for integrases, when used in combinations with other anti-HIV agents it can provide a combination therapy with fewer side effects for humans.

  本发明涉及一种联合治疗HIV感染或抑制整合酶的组合疗法，包括（S）-6-（3-氯-2-氟苯基）-1-（1-羟甲基-2-甲基丙基）-7-甲氧基-4-氧代-1，4-二氢喹啉-3-羧酸（“化合物A”）或其药学上可接受的溶剂化物或盐与至少一种其他抗HIV剂的联合使用。在本发明的某些实施例中，其他抗HIV药物选择自反转录酶抑制剂和蛋白酶抑制剂。在本发明的某些实施例中，其他抗HIV剂选择自AZT，3TC，PMPA，依法韦伦，印地那韦，奈非那韦，AZT / 3TC的组合和PMPA / 3TC的组合。由于化合物A具有高特异性抑制整合酶的活性，当与其他抗HIV药物联合使用时，可以为人类提供更少的副作用的联合治疗。